# reload+after+2024-01-23 20:46:28.699126
address1§1185 Avenue of the Americas
address2§3rd Floor
city§New York
state§NY
zip§10036
country§United States
phone§844 967 2633
website§https://www.oramed.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Nadav  Kidron Esq.', 'age': 49, 'title': 'President, CEO & Executive Chairman', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 1110999, 'exercisedValue': 0, 'unexercisedValue': 3953022}, {'maxAge': 1, 'name': 'Mr. David  Silberman CPA', 'age': 39, 'title': 'CFO & Treasurer', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 248041, 'exercisedValue': 0, 'unexercisedValue': 38546}, {'maxAge': 1, 'name': 'Dr. Miriam  Kidron Ph.D.', 'age': 83, 'title': 'Chief Scientific Officer & Director', 'yearBorn': 1940, 'fiscalYear': 2022, 'totalPay': 542679, 'exercisedValue': 0, 'unexercisedValue': 2157492}, {'maxAge': 1, 'name': 'Mr. Joshua  Hexter', 'age': 53, 'title': 'Chief Operating & Business Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 326943, 'exercisedValue': 0, 'unexercisedValue': 799500}, {'maxAge': 1, 'name': 'Mr. Netanel  Derovan', 'age': 47, 'title': 'Chief Legal Officer & Company Secretary', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.775
priceToSalesTrailing12Months§49.301003
currency§USD
dateShortInterest§1702598400
forwardEps§-0.11
exchange§NCM
quoteType§EQUITY
shortName§Oramed Pharmaceuticals Inc.
longName§Oramed Pharmaceuticals Inc.
firstTradeDateEpochUtc§1178026200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§10d9608c-9a03-3ae5-be91-efa85e1fca6a
gmtOffSetMilliseconds§-18000000
targetHighPrice§4.3
targetLowPrice§4.3
targetMeanPrice§4.3
targetMedianPrice§4.3
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§2.239
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
